CureVac N.V. (ETR: 5CV)

Market Cap	893.66M
Revenue (ttm)	65.86M
Net Income (ttm)	-278.43M
Shares Out	n/a
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186,816
Average Volume	314,142
Open	4.092
Previous Close	4.114
Day's Range	3.952 - 4.124
52-Week Range	2.110 - 4.808
Beta	2.61
RSI	60.35
Earnings Date	Apr 25, 2025

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 1,172
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 5CV

Financial Performance

In 2023, CureVac's revenue was 53.76 million, a decrease of -20.26% compared to the previous year's 67.42 million. Losses were -260.17 million, 4.47% more than in 2022.